Literature DB >> 11948555

Contributions of saturable active secretion, passive transcellular, and paracellular diffusion to the overall transport of furosemide across adenocarcinoma (Caco-2) cells.

Shawn D Flanagan1, Lpori H Takahashi, Xiaoli Liu, Leslie Z Benet.   

Abstract

Furosemide permeation across Caco-2 cells was investigated to determine if previously reported directional differences in transport rates are due to a saturable, energy dependent process. In addition, studies were carried out to determine the route of permeation for this drug. By comparing apical (A) to basolateral (B) and B to A directional transport across Caco-2 cells, a saturable, nonlinear component to furosemide transport was observed. Transport in the secretory direction was fit to yield the following apparent parameters K(m) = 63 +/- 28 microM, V(max) = 436 +/- 137 pmol/cm(2)h, and P(app) = 3.7 +/- 0.9 x 10(-7) cm/s. Evidence of energy dependence was demonstrated using both metabolic inhibition, and transport against a diffusion gradient methods. Disruption of tight junctions by use of the calcium chelator, EGTA, caused a significant increase in furosemide transport (twofold and 12-fold increases in B to A and A to B, respectively) indicating the importance of the paracellular route. We conclude that furosemide secretion from Caco-2 cells is the result of saturable active transport and passive diffusion that has a significant paracellular component. Copyright 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 91: 1169-1177, 2002

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948555     DOI: 10.1002/jps.10099

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  10 in total

Review 1.  Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research.

Authors:  Céline Passeleu-Le Bourdonnec; Pierre-Alain Carrupt; Jean Michel Scherrmann; Sophie Martel
Journal:  Pharm Res       Date:  2013-06-26       Impact factor: 4.200

2.  Reconciling Human-Canine Differences in Oral Bioavailability: Looking beyond the Biopharmaceutics Classification System.

Authors:  Marilyn N Martinez; Ayman El-Kattan; Elias Awji; Mark Papich
Journal:  AAPS J       Date:  2019-08-08       Impact factor: 4.009

3.  Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers.

Authors:  Staffan Tavelin; Jan Taipalensuu; Lauri Söderberg; Rick Morrison; Saeho Chong; Per Artursson
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

4.  Effects of extracts of commonly consumed food supplements and food fractions on the permeability of drugs across Caco-2 cell monolayers.

Authors:  Leena A Laitinen; Päivi S M Tammela; Anna Galkin; Heikki J Vuorela; Martti L A Marvola; Pia M Vuorela
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

5.  Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls.

Authors:  Mark G Papich; Marilyn N Martinez
Journal:  AAPS J       Date:  2015-04-29       Impact factor: 4.009

6.  Characterization of the uptake mechanism for a novel loop diuretic, M17055, in Caco-2 cells: involvement of organic anion transporting polypeptide (OATP)-B.

Authors:  Tomohiro Nishimura; Yoshiyuki Kubo; Yukio Kato; Yoshimichi Sai; Takuo Ogihara; Akira Tsuji
Journal:  Pharm Res       Date:  2006-11-14       Impact factor: 4.580

Review 7.  Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions.

Authors:  Jean-Marie Nicolas; François Bouzom; Chanteux Hugues; Anna-Lena Ungell
Journal:  Biopharm Drug Dispos       Date:  2017-02-06       Impact factor: 1.627

8.  Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions.

Authors:  Hannah Britz; Nina Hanke; Mitchell E Taub; Ting Wang; Bhagwat Prasad; Éric Fernandez; Peter Stopfer; Valerie Nock; Thorsten Lehr
Journal:  Pharm Res       Date:  2020-11-25       Impact factor: 4.200

Review 9.  Overcoming the blood-brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches.

Authors:  Ksenia Mitusova; Oleksii O Peltek; Timofey E Karpov; Albert R Muslimov; Mikhail V Zyuzin; Alexander S Timin
Journal:  J Nanobiotechnology       Date:  2022-09-15       Impact factor: 9.429

10.  Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective.

Authors:  Arian Emami Riedmaier; Kevin DeMent; James Huckle; Phil Bransford; Cordula Stillhart; Richard Lloyd; Ravindra Alluri; Sumit Basu; Yuan Chen; Varsha Dhamankar; Stephanie Dodd; Priyanka Kulkarni; Andrés Olivares-Morales; Chi-Chi Peng; Xavier Pepin; Xiaojun Ren; Thuy Tran; Christophe Tistaert; Tycho Heimbach; Filippos Kesisoglou; Christian Wagner; Neil Parrott
Journal:  AAPS J       Date:  2020-09-27       Impact factor: 4.009

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.